Adult Clinical Trials:GASTROINTESTINAL

RTOG 0529:  GASTROINTESTINAL

A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal

• Histologically-proven, invasive primary squamous, basaloid, or cloacogenic carcinoma of the anal canal; T stage 2-4 and N0-N3 stage
•  Zubrod Performance Status 0-1; Age > 18
•  Adequate bone marrow, hepatic and renal function as defined in the protocol
•  Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study.
• If there is clinical suspicion of AIDS, an HIV test must be done within 42 days prior to registration. Note: HIV positive patients without AIDS are eligible for this trial. Patients must sign a study-specific informed consent prior to study entry.

Treatment

IMRT
5-FU + Mitomycin-C on days 1 and 29 of RT